Acadia Pharmaceuticals: New Daybue Drug Already Showing Signs Of Slowing


  • Acadia’s DAYBUE drug to treat Rett Syndrome has disappointed recently.
  • DAYBUE patients suffer from side effects that make the drug difficult to continue using.
  • Several senior insiders have left the company recently, and remaining insiders have continued to exercise options and sell their shares.
  • I’m taking a negative view of the company’s stock price going forward until DAYBUE can prove it’s a viable and growing drug.

Pharmacist using a digital tablet to do inventory in a pharmacy

ZeynepKaya/E+ via Getty Images


ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) is a biotech company currently selling two drugs: NUPLAZID, which treats Parkinson’s Disease, and the recently launched DAYBUE, which treats the extremely rare Rett Syndrome. ACAD has at least 5 other drugs currently in the

Analyst’s Disclosure: I/we have a beneficial short position in the shares of ACAD either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

I am short shares and have options positions with an overall negative delta that will profit in the event of a decline in the stock price.

Seeking Alpha’s Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Leave a Reply

Your email address will not be published. Required fields are marked *